These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36074799)

  • 21. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis.
    Patel J; Bettencourt R; Cui J; Salotti J; Hooker J; Bhatt A; Hernandez C; Nguyen P; Aryafar H; Valasek M; Haufe W; Hooker C; Richards L; Sirlin CB; Loomba R
    Therap Adv Gastroenterol; 2016 Sep; 9(5):692-701. PubMed ID: 27582882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
    Mamidipalli A; Fowler KJ; Hamilton G; Wolfson T; Covarrubias Y; Tran C; Fazeli S; Wiens CN; McMillan A; Artz NS; Funk LM; Campos GM; Greenberg JA; Gamst A; Middleton MS; Schwimmer JB; Reeder SB; Sirlin CB
    Eur Radiol; 2020 Sep; 30(9):5120-5129. PubMed ID: 32318847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with oligonol, a low-molecular polyphenol derived from lychee fruit, attenuates diabetes-induced hepatic damage through regulation of oxidative stress and lipid metabolism.
    Noh JS; Park CH; Yokozawa T
    Br J Nutr; 2011 Oct; 106(7):1013-22. PubMed ID: 21477406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.
    Noureddin M; Lam J; Peterson MR; Middleton M; Hamilton G; Le TA; Bettencourt R; Changchien C; Brenner DA; Sirlin C; Loomba R
    Hepatology; 2013 Dec; 58(6):1930-40. PubMed ID: 23696515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
    Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
    Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
    Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease.
    Chen J; Duan S; Ma J; Wang R; Chen J; Liu X; Xue L; Xie S; Yao S
    Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):754-761. PubMed ID: 32091437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study).
    Cho Y; Rhee H; Kim YE; Lee M; Lee BW; Kang ES; Cha BS; Choi JY; Lee YH
    BMC Med; 2022 Mar; 20(1):93. PubMed ID: 35307033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
    Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
    Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of Liver Fat by MRI-PDFF Imaging in Patients with Suspected Non-alcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome, Liver Function Test and Ultrasonography.
    Rodge GA; Goenka MK; Goenka U; Afzalpurkar S; Shah BB
    J Clin Exp Hepatol; 2021; 11(5):586-591. PubMed ID: 34511820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
    Flint A; Andersen G; Hockings P; Johansson L; Morsing A; Sundby Palle M; Vogl T; Loomba R; Plum-Mörschel L
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1150-1161. PubMed ID: 34570916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypolipidaemic and antioxidative effects of oligonol, a low-molecular-weight polyphenol derived from lychee fruit, on renal damage in type 2 diabetic mice.
    Noh JS; Kim HY; Park CH; Fujii H; Yokozawa T
    Br J Nutr; 2010 Oct; 104(8):1120-8. PubMed ID: 20642878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
    Jiang H; Chen HC; Lafata KJ; Bashir MR
    Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligonol Ameliorates CCl₄-Induced Liver Injury in Rats via the NF-Kappa B and MAPK Signaling Pathways.
    Bak J; Je NK; Chung HY; Yokozawa T; Yoon S; Moon JO
    Oxid Med Cell Longev; 2016; 2016():3935841. PubMed ID: 26798422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease.
    Wang X; Zhang X; Ma L; Li S
    Sci China Life Sci; 2018 Sep; 61(9):1107-1114. PubMed ID: 29934919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.